Laboratory of Cellular and Molecular Immunology, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, MG, Brazil; Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Vaccine. 2015 Jan 3;33(2):280-8. doi: 10.1016/j.vaccine.2014.11.039. Epub 2014 Dec 1.
Live attenuated Leishmania donovani parasites such as LdCen(-/-) have been shown elicit protective immunity against leishmanial infection in mice and hamster models. Previously, we have reported on the induction of strong immunogenicity in dogs upon vaccination with LdCen(-/-) including an increase in immunoglobulin isotypes, higher lymphoproliferative response, higher frequencies of activated CD4(+) and CD8(+) T cells, IFN-γ production by CD8(+) T cells, increased secretion of TNF-α and IL-12/IL-23p40 and, finally, decreased secretion of IL-4. To further explore the potential of LdCen(-/-) parasites as vaccine candidates, we performed a 24-month follow up of LdCen(-/-) immunized dogs after challenge with virulent Leishmania infantum, aiming determination of parasite burden by qPCR, antibody production (ELISA) and cellular responses (T cell activation and cytokine production) by flow cytometry and sandwich ELISA. Our data demonstrated that vaccination with a single dose of LdCen(-/-) (without any adjuvant) resulted in the reduction of up to 87.3% of parasite burden after 18 months of virulent challenge. These results are comparable to those obtained with commercially available vaccine in Brazil (Leishmune(®)). The protection was associated with antibody production and CD4(+) and CD8(+) proliferative responses, as well as T cell activation and significantly higher production of IFN-γ, IL-12/IL-23p40 and TNF-α, which was comparable to responses induced by immunization with Leishmune(®), with significant differences when compared to control animals (Placebo). Moreover, only animals immunized with LdCen(-/-) expressed lower levels of IL-4 when compared to animals vaccinated either with Leishmune(®) or PBS. Our results support further studies aiming to demonstrate the potential of genetically modified live attenuated L. donovani vaccine to control L. infantum transmission in endemic areas for CVL.
经证明,活减毒利什曼原虫寄生虫,如 LdCen(-/-),可在小鼠和仓鼠模型中引发针对利什曼原虫感染的保护性免疫。此前,我们曾报道过,在犬中接种 LdCen(-/-)后可诱导出强烈的免疫原性,包括免疫球蛋白同种型增加、更高的淋巴细胞增殖反应、更高频率的激活 CD4(+)和 CD8(+)T 细胞、CD8(+)T 细胞产生 IFN-γ、TNF-α和 IL-12/IL-23p40 的分泌增加,最后,IL-4 的分泌减少。为了进一步探索 LdCen(-/-)寄生虫作为疫苗候选物的潜力,我们对用强毒利什曼原虫婴儿利什曼原虫攻击后的 LdCen(-/-)免疫犬进行了 24 个月的随访,旨在通过 qPCR 确定寄生虫负担、抗体产生(ELISA)和细胞反应(T 细胞激活和细胞因子产生)通过流式细胞术和夹心 ELISA。我们的数据表明,单次接种 LdCen(-/-)(无任何佐剂)可将 18 个月后强毒攻击的寄生虫负担减少多达 87.3%。这些结果与巴西市售疫苗(Leishmune(®))获得的结果相当。保护作用与抗体产生以及 CD4(+)和 CD8(+)增殖反应以及 T 细胞激活和 IFN-γ、IL-12/IL-23p40 和 TNF-α的显著更高产生相关,这与用 Leishmune(®)免疫诱导的反应相当,与对照动物(安慰剂)相比有显著差异。此外,与用 Leishmune(®)或 PBS 接种的动物相比,只有用 LdCen(-/-)免疫的动物表达的 IL-4 水平较低。我们的结果支持进一步研究,旨在证明基因修饰的活减毒利什曼原虫疫苗控制地方性犬利什曼病传播的潜力。